TriSalus Announces Leadership Changes
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc., (Nasdaq: TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team.James (Jim) Young, who previously served as the Company’s Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company’s Chief Financial Officer. In this role, Mr. Young succeeds Sean Murphy, who will continue to serve the Company as Chief Manufacturing, Strategy and Business Development Officer and as a member of the Board of Directors. The Company also promoted Dr. Richard B. Marshak to Chief Commercial Officer and Jodi Devlin to Chief of Clinical Strategy a
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript [Seeking Alpha]Seeking Alpha
- TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025Business Wire
TLSI
Earnings
- 11/13/25 - Miss
TLSI
Analyst Actions
- 12/17/25 - Canaccord Genuity
TLSI
Sec Filings
- 12/5/25 - Form EFFECT
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- TLSI's page on the SEC website